Abstract Number: 1385 • 2012 ACR/ARHP Annual Meeting
Increased Body Mass Index in Ankylosing Spondylitis Is Associated with a Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise
Background/Purpose: In Ankylosing Spondylitis (AS) the effect of obesity on disease characteristics and exercise perceptions is unknown. Exercise is an essential component in the management…Abstract Number: 598 • 2012 ACR/ARHP Annual Meeting
The Non-Synonymous Polymorphism IL23R Arg381Gln Is Associated with Ankylosis in Spondyloarthritis
Background/Purpose: Spondyloarthritis (SpA) is a group of articular disorders sharing genetic background. Single-nucleotide polymorphisms (SNP) of the interleukin 23 receptor (IL23R) gene have been reproducibly…Abstract Number: 2213 • 2012 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Is Strongly Related to Clinical Spine Fractures Independently of Drugs Use: A Register-Based Case-Control Study
TITLE: "Ankylosing Spondylitis is strongly related to clinical spine fractures independently of drugs use: a register-based case-control study."Background/Purpose: Ankylosing Spondylitis (AS) is associated not only…Abstract Number: 1356 • 2012 ACR/ARHP Annual Meeting
Gender Differences Among Spondylitis Associated with Psoriasis, Inflammatory Bowel Disease and Primary Ankylosing Spondylitis
Background/Purpose: Differences regarding gender in primary Ankylosing Spondylitis are well known. However, there is less evidence regarding Spondylitis Associated with Psoriasis and that associated with…Abstract Number: 599 • 2012 ACR/ARHP Annual Meeting
LIGHT (TNFSF14), Cathepsin K, DKK-1 and Sclerostin in Ankylosing Spondylitis: Osteoclast/OSTEOBLAST Imbalance Unrelated to Disease Activity and Effect of ANTI-TNFα Treatment On the WNT/β Catenin Pathway
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory arthritis characterized by erosions and new bone formation. These processes appear to be related by the fine balance…Abstract Number: 2219 • 2012 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Show Similar Response Rates After One Year of Treatment with Etanercept – results of the Esther Trial
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration < 5 years we assessed whether there is a difference to etanercept (ETA)…Abstract Number: 1363 • 2012 ACR/ARHP Annual Meeting
Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis
Background/Purpose: Comorbidities can importantly influence the results of clinical studies on functional outcomes as they may act as confounders or effect modifiers. The generic self-administered…Abstract Number: 571 • 2012 ACR/ARHP Annual Meeting
Description of Distribution of Active Inflammatory Lesions On Magnetic Resonance Imaging of the Sacroiliac Joints and the Spine in Patients with Early Axial Spondyloarthritis – Analysis of the Esther Trial Baseline Data
Background/Purpose: To address the question whether active inflammation starts at specific sites of the sacroiliac joints (SI-joints) and/ or the spine. Methods: Wb-MRIs of…Abstract Number: 2220 • 2012 ACR/ARHP Annual Meeting
Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry
Background/Purpose: The spondyloarthritides are a group of conditions characterized by inflammation in the axial skeleton or peripheral joints. The arthritis may present as the primary…Abstract Number: 1366 • 2012 ACR/ARHP Annual Meeting
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo – Controlled Study
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo-Controlled StudyBackground/Purpose: This…Abstract Number: 575 • 2012 ACR/ARHP Annual Meeting
Profiling of Response to Anti-TNFα Therapy by Serum Markers of Tissue Degradation End Products in Ankylosing Spondylitis Patients
Background/Purpose: Chronic inflammatory diseases such as Ankylosing Spondylitis (AS) are diverse and therefore hard to clearly diagnose and treat. Conventional biomarkers for AS, as CRP…Abstract Number: 1925 • 2012 ACR/ARHP Annual Meeting
Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Title: Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Background/Purpose: Golimumab (GLM), adalimumab…Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting
Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…Abstract Number: 583 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study
Background/Purpose: To estimate the risk of ankylosing spondylitis (AS) among individuals with affected first-degree relatives and to assess the magnitude of genetic contribution to the…Abstract Number: 1851 • 2012 ACR/ARHP Annual Meeting
Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis
Background/Purpose: Infection with methicillin-resistant Staphylococcus aureus (MRSA) is a source of significant morbidity/mortality. Health-care entities spend large amounts to prevent spread of MRSA. Most MRSA…
ACR Meeting Abstracts